Document Detail


Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease.
MedLine Citation:
PMID:  21559977     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
AIM: To evaluate the role of postchemotherapy FDG PET and compare it with other predictive factors in paediatric Hodgkin's disease (HD). MATERIALS AND METHODS: In this retrospective study, 98 paediatric patients with HD (enrolled in eight Italian centres) were analysed. Their mean age was 13.8 years (range 5-19 years). A PET scan was performed at the end of chemotherapy and reported as positive or negative on the basis of visual and/or semiquantitative analysis. True outcome was defined as remission or disease on the basis of combined criteria (clinical, instrumental and/or histological) with a mean follow-up period of 25 months. Statistical analyses were performed for the postchemotherapy PET results and other potential predictive factors (age cut-off, stage, presence of bulky masses and therapeutic group) with respect to patient outcome and progression-free survival (PFS). RESULTS: Overall the patients had a mean PFS of 23.5 months (range 4-46 months): 87 achieved remission (88.8%) and 11 showed disease. Of the 98 patients, 17 were positive on postchemotherapy PET . Seven patients (41%) showed disease during follow-up, and relapse occurred in only four out of the 81 patients who were negative on PET (p = 0.0001). Kaplan-Meier analysis demonstrated significant correlations between PFS and the postchemotherapy PET result (p = 0.0001) and a cut-off age at diagnosis of 13.3 years (p = 0.0337), whereas disease stage (p = 0.7404), therapeutic group (p = 0.5240) and presence of bulky masses (p = 0.2208) were not significantly correlated with PFS. Multivariate analysis confirmed a statistically significant correlation with PFS only for the postchemotherapy PET findings (p = 0.0009). CONCLUSION: In paediatric HD, age at diagnosis and postchemotherapy PET results are the main predictors of patient outcome and PFS, with FDG PET being the only independent predictive factor for PFS.
Authors:
Egesta Lopci; Roberta Burnelli; Luca Guerra; Angelina Cistaro; Arnoldo Piccardo; Pietro Zucchetta; Enrico Derenzini; Alessandra Todesco; Alberto Garaventa; Fabio Schumacher; Piero Farruggia; Salvatore Buffardi; Alessandra Sala; Fiorina Casale; Paolo Indolfi; Samanta Biondi; Andrea Pession; Stefano Fanti
Related Documents :
1322167 - Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small...
14707497 - Phase ii study of interferon gamma in malignant carcinoid tumors (e9292): a trial of th...
9679527 - A phase ii study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patient...
21486867 - Diffuse large b-cell lymphoma with involvement of the kidney: outcome and risk of centr...
19317257 - A retrospective analysis of twenty-eight borderline ovarian tumours in adolescent girls.
12682787 - Durable complete clinical responses in a phase i/ii trial using an autologous melanoma ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-11
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  -     ISSN:  1619-7089     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Nuclear Medicine Department, University Hospital S. Orsola-Malpighi, Via Massarenti, 9, CAP 40138, Bologna, Italy, egesta.lopci@gmail.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cell physiology rather than enzyme kinetics can determine the efficiency of cytochrome P450-catalyze...
Next Document:  Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with i...